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Abstract
Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoen-
cephalopathy (CADASIL) is a familial fatal progressive degenerative disorder. One of
the pathological hallmarks of CADASIL is a dramatic reduction of vascular smooth
muscle cells (VSMCs) in cerebral arteries. Using VSMCs from the vasculature of the
human umbilical cord, placenta and cerebrum of CADASIL patients, we found that
CADASIL VSMCs had a lower proliferation rate compared to control VSMCs. Expo-
sure of control VSMCs and endothelial cells (ECs) to media derived from CADASIL
VSMCs lowered the proliferation rate of all cells examined. By quantitative RT-PCR
analysis, we observed increased Transforming growth factor-b (TGFb) gene expres-
sion in CADASIL VSMCs. Adding TGFb-neutralizing antibody restored the prolifera-
tion rate of CADASIL VSMCs. We assessed proliferation differences in the presence
or absence of TGFb-neutralizing antibody in ECs co-cultured with VSMCs. ECs
co-cultured with CADASIL VSMCs exhibited a lower proliferation rate than those
co-cultured with control VSMCs, and neutralization of TGFb normalized the prolifer-
ation rate of ECs co-cultured with CADASIL VSMCs. We suggest that increased
TGFb expression in CADASIL VSMCs is involved in the reduced VSMC proliferation
in CADASIL and may play a role in situ in altered proliferation of neighbouring cells
in the vasculature.
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1 | INTRODUCTION
Cerebral autosomal-dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL) is the most common form of
hereditary small vessel disease and is the most common genetic
cause of stroke and vascular dementia in adults.1,2 The clinical pre-
sentation of CADASIL is characterized by migraine with aura, tran-
sient neurological symptoms, mood disturbances and cognitive
impairment.3-7 Pathological characteristics evident in the brain of
patients with CADASIL include deposits of granular osmiophilic
material (GOM) in close vicinity to the basement membrane that sur-
rounds vascular smooth muscle cells (VSMCs) of parenchymal arteri-
oles,8,9 and degeneration of VSMCs 10,11 in small and medium-sized
arteries.12,13 Subsequent to VSMC degeneration, fibrotic thickening
of the vessel walls and narrowing of the lumina of small penetrating
arterioles occur predominantly in cerebral white matter.14 The result-
ing blood flow restriction leads to characteristic ischaemic changes,
white matter loss and lacunar infarcts.14 White matter changes
observed via magnetic resonance imaging (MRI) are a characteristic
feature of CADASIL that have been utilized as an indication of the
disease.15,16
CADASIL is caused by mutations in the NOTCH3 gene. NOTCH3
is a type I transmembrane receptor belonging to the Notch signalling
family, one of a group of “elite” intracellular signalling pathways.17,18
Currently, more than 230 different CADASIL-causing mutations in
the NOTCH3 gene have been detected,19 which are either missense
mutations or small in-frame deletions in the epidermal growth factor
repeats of NOTCH3. These mutations affect the number of cysteine
residues, leading to an unpaired cysteine residue.20-24
In CADASIL, pathological observations have shown abnormality
in numerous cells within neurovascular units, including VSMCs and
endothelial cells (ECs).25,26 Therefore, alterations to each cell type
within the neurovascular unit can affect the vulnerability of blood
vessels in CADASIL.25 In CADASIL, the outer layer of the vessels
consisting of VSMCs becomes thinner, while the endothelial layer
that is surrounded by the VSMCs becomes swollen and loses its
integrity due to gap junction loss.25,26 This leads to microbleeds,
occlusion and/or thrombosis.27,28
It has been proposed that the degeneration of the smooth
muscle layer in arteries/arterioles of patients with CADASIL is the
result of increased VSMC death.11,29 There is meagre evidence
that the thinning of the tunica media is due to VSMC loss or
degeneration by cell death. In a recent study, we suggested that
the reduced number of cells is rather due to impaired VSMC pro-
liferation.29 We showed that VSMCs from CADASIL patients with
the R133C mutation in NOTCH3 have a lower proliferation rate
than control VSMCs.29
Transforming growth factor-b (TGFb) is a cytokine that has
multicellular function in the cells and has a great involvement in the
fibrosis of several diseases. The role of TGFb in cell proliferation is
well-established.30 Dysregulation of the TGFb signalling pathway has
been proposed in CADASIL by showing increased levels of the TGFb
pro-domain.31 Furthermore, latent TGFb binding protein 1 (LTBP-1)
has been found co-localized with NOTCH3 extracellular domain
deposits in CADASIL tissues. Transforming growth factor-b signalling
has also been demonstrated to play a role in the promotion and
maintenance of the contractile phenotype of VSMCs. Three TGFb
isoforms (TGFb1, TGFb2 and TGFb3) have been identified in mam-
mals, which are encoded by different genes but have high structural
homology. Transforming growth factor-b binds to membrane recep-
tors bearing serine/threonine kinase activity, namely TGFb receptors
(TGFbR). The TGFb isoforms have similar cellular signalling targets
on the TGFb receptors which exist in I, II, III and V subtypes.32 The
expression level of TGFb-receptors is important for the TGFb sig-
nalling pathway.33
This study aimed to investigate why VSMC proliferation is
impaired in CADASIL. Using immortalized human umbilical, placental
and cerebral VSMCs derived from individuals carrying the R133C
mutation or control NOTCH3, we report a role of TGFb in VSMC
and EC proliferation rates, suggesting it is a critical mechanism
involved in CADASIL pathophysiology.
2 | MATERIAL AND METHODS
2.1 | Cell lines and genotyping
Patient-derived VSMC cell lines: umbilical cord (Umb)- and placental
(Pla) VSMCs were established from blood vessels of genetically veri-
fied patients with CADASIL and control subjects as previously
described.34,35 The genotyping of the cerebral arterial (Cer) VSMC
cell line 35 was also verified (Figure S1A).
2.2 | Cell culture
Patient-derived VSMC cell lines: Umb-,29 Pla- and CerVSMC and
human foreskin fibroblasts were cultured as described previ-
ously.35,36 Umbilical artery smooth muscle cells (UASMC, Lonza)
were cultured in smooth muscle cell medium BulletKit according to
the manufacturer’s instructions or cultured in M 231 medium with
smooth muscle growth supplement (Life Technologies). Human aortic
ECs (Life Technologies) were cultured in M 200 medium with low
serum growth supplement (ThermoFisher Scientific).
2.3 | Cell proliferation rate examination
CellTrace carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen)
was used to enable the measurement of VSMC proliferation. Car-
boxyfluorescein succinimidyl ester is a membrane permeant fluores-
cein-based dye that can be used to track cell division due to the
progressive halving of the fluorescence intensity of the dye in cells
after each division. Briefly, CADASIL and control VSMC were grown
to 90% confluence and harvested after washing twice with PBS. The
cells were centrifuged and re-suspended with 1 mL pre-warmed PBS
followed by labelling with 1 lmol/L CFSE for 10 minutes at 37°C.
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Equal numbers of CFSE-labelled cells were incubated for either 3 or
7 days. Unlabelled cells were used as negative controls. Flow cytom-
etry was performed using a FACSCalibur™ Cytometry, and data were
analysed using the CellQuest software (BD Biosciences). The prolif-
eration rate of VSMCs was also investigated using immunofluores-
cent staining of the proliferation-associated Ki67 protein as
previously described.29 The quantification of Ki67 positive cells was
based on the evaluation of at least 500 cells.
2.4 | Exposure of fibroblasts and VSMC to
CADASIL PlaVSMC-conditioned medium
Human fibroblasts and UASMC were exposed to media that CADA-
SIL PlaVSMC cells were grown in conditioned medium for 24 hour,
and 3 and 7 days. The PlaVSMC-conditioned medium was applied
either undiluted or diluted 1:1 with complete medium. The prolifera-
tion rate of VSMCs was investigated using immunofluorescence
staining of the proliferation-associated Ki67 protein as described
previously.29 The ratio of Ki67 positive cells was based on the evalu-
ation of at least 500 cells. Experiments were performed in triplicate.
2.5 | Quantitative real-time polymerase chain
reaction (qRT-PCR) of genes related to cell
proliferation
RNA was isolated from Pla- and CerVSMC using the RNeasy Mini
kit (QIAGEN). The quality of RNA was determined with RIN (RNA
Integrity Number) of 10 (Figure S1B). cDNA was synthesized using
the SuperScript VILO cDNA Synthesis kit (ThermoFisher Scientific)
according to the manufacturer’s protocol. qRT-PCR was performed
using the TaqMan Array targeting human cyclins and cell cycle regu-
lation-associated genes, genes encoding members of the TGFb
superfamily of ligands and four endogenous control genes (Thermo-
Fisher Scientific). The TaqMan Array Human TGFb pathway plate
(ThermoFisher Scientific) was used for co-culture studies. All Taq-
Man Probe qRT-PCR reactions were performed in triplicate in 1 9
TaqMan Fast Advanced Master Mix (Life Technologies) with 30 ng
of cDNA. Quantitative RT-PCR was performed on a 7500 Fast Real-
Time PCR System (Life Technologies). The expression of genes was
normalized to the endogenous control gene; HPRT1, and the RQ
(Relative Quantitation) was calculated using control VSMC as a refer-
ence. Each experiment and the control value were normalized to 1.
2.6 | Transforming growth factor-beta (TGFb)
antibody
Transforming growth factor-b pan-specific neutralizing antibody was
derived from recombinant human TGFb1, porcine platelet-derived
TGFb1.2, porcine platelet-derived TGFb2 and recombinant amphib-
ian TGFb5 porcine platelet-derived TGFb1 and 2, which detects
TGFb1,TGFb1.2, TGFb2, TGFb3 and TGFb5 (AB-100-NA, R&D sys-
tems). Vascular smooth muscle cells was seeded at 5 9 104 cells/mL
in 24 well plates and cultured overnight. The medium was then
changed and cells were incubated in the presence or absence of
12 lg/mL TGFb-neutralizing antibody for 24 hour. Vascular smooth
muscle cells or ECs were fixed and stained with Ki67 antibody as
described earlier.
2.7 | Co-culture of VSMCs and ECs in transwell
system
To examine the effect of TGFb produced by VSMC on EC prolifera-
tion rates, Pla- and CerVSMC were co-cultured with ECs in a non-
contacting co-culture transwell system (Pore size 0.4 lm, Life Tech-
nologies). Endothelial cells were plated at 5 9 104 cells/mL in 6- or
24-well plates. Pla- and CerVSMCs were seeded at 5 9 104 cells/
mL onto the membrane of transwell cell culture inserts and allowed
to grow overnight. After 24 hour, the transwell insert membrane
containing the VSMCs was placed into plates containing ECs. Vascu-
lar smooth muscle cells were treated with a TGFb-neutralizing anti-
body (12 lg/mL).
2.8 | Statistical analysis
Statistical comparison of values obtained for VSMC cell lines was
analysed by one-way ANOVA followed by Bonferroni’s post hoc
test. Student t-test was used for two-group comparisons. P-values
<.05 were considered significant. The results are representative of
three independent biological replicates expressed as mean  SEM.
3 | RESULTS
3.1 | Proliferation rate in VSMCs with CADASIL
mutation
To examine the proliferation rate in PlaVSMC and CerVSMC, we
labelled cells with CFSE dye for flow cytometry or stained with Ki67
antibody for confocal microscopy (Figure 1A-D). A representative
flow cytometric histogram illustrating CFSE fluorescence in CADASIL
and control PlaVSMCs is shown in Figure 1A. Fluorescence his-
togram demonstrated the number of control PlaVSMCs with intense
CFSE signal markedly decreased from base line (day 0) (Figure 1A,
right and left panel), confirming that the control PlaVSMCs were
actively proliferating as compared to CADASIL PlaVSMCs after 3
and 7 days (Figure 1A). Analysis demonstrated the number of
CADASIL PlaVSMCs with strong CFSE fluorescence intensity indicat-
ing undivided cells was notably higher compared to control
PlaVSMCs after 3 days (Figure 1B). The decrease in CFSE-stain
intensity indicating divided cells, in control PlaVSMCs compared to
CADASIL PlaVSMCs, 3 days post-CFSE labelling shows a signifi-
cantly higher proliferation activity in control PlaVSMCs compared to
CADASIL PlaVSMCs (Figure 1B, P < .05). Reduced CADASIL
UmbVSMCs proliferation rate (divided) compared to control
UmbVSMCs was also confirmed 29 (Figure S2, P < .01).
Proliferation was further evaluated by anti-Ki67 staining and
confocal microscopy (Figure 1C). A lower number of Ki67 positive
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cells were present for CADASIL CerVSMCs compared to control
CerVSMCs (Figure 1C and D, P < .01).
3.2 | The effect of CADASIL VSMC-conditioned
medium on proliferation of fibroblasts and VSMCs
Next, we questioned whether the decreased proliferation rate
observed in CADASIL VSMCs is solely an intracellular event or
whether it influences neighbouring cells. Confocal microscopy and
Ki67 staining demonstrated human foreskin fibroblasts cultured in
CADASIL PlaVSMC-conditioned medium displayed a lower prolifera-
tion rate when compared to fibroblasts cultured in control
PlaVSMCs-conditioned medium (Figure 2A, P < .01). A decreased
proliferation rate was also observed when two different conditioned
medium dilutions (1:1 and 1:2) from CADASIL PlaVSMCs were
added to the commercial UASMC cell line (Figure 2B); however, the
decrease was not significant. To assess the effect of CADASIL
VSMCs on control VSMCs proliferation, we directly co-cultured
CADASIL VSMCs with control VSMCs. Overall, we observed an inhi-
bitory effect of CADASIL VSMCs on proliferation rate of control pla-
cental and umbilical VSMCs (Figure S3A, B).
3.3 | Elevated TGFb gene expression in CADASIL
VSMC
To identify candidate factors secreted by CADASIL VSMC that could
result in a lower proliferation rate of neighbouring cells, we moni-
tored the expression level of several genes in the cell proliferation
pathway by qRT-PCR. We identified a number of genes with altered
expression levels in CADASIL Pla- and CerVSMCs as compared to
their control counterparts (Table S1, data not shown, respectively).
We found an increase expression of all TGFb isoform families
F IGURE 1 Quantification of proliferation rates in Pla- and CerVSMCs. A, A representative flow cytometric histogram illustrating
carboxyfluorescein succinimidyl ester (CFSE) fluorescence in PlaVSMCs over 3 and 7 days. Control PlaVSMCs (green line) shows markedly
decreased CFSE intensity from baseline at days 3 and 7. Cerebral autosomal-dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL) PlaVSMCs (pink line) CFSE intensity decreased over a longer period of time than in the control PlaVSMCs. B,
The graph shows the proportion of divided and undivided PlaVSMCs after 3 days in culture. The undivided population represents cells with
low or non-proliferative capability (unchanged and/or higher CFSE-staining). C, D, Representative confocal images of Ki67 staining (green) in
CADASIL vs control CerVSMCs are shown. DAPI (cell nucleus; blue). Scale bar = 10 lm. ***P < .001, **P < .01,*P < .05. The results are
representative of three independent biological replicates (n = 3). Student t-test was used for two-group comparisons
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(TGFb1, -2 and 3) in CADASIL VSMCs compared to control VSMCs
as quantified by qRT-PCR. However, the increased level of TGFb3
was more obvious as compared to the TGFb1, -2. Notably, the
expression of TGFb3 was significantly higher in both CADASIL Pla-
and CerVSMCs compared to control VSMCs (Figure 2C and D,
P < .001, respectively). Next, we investigated whether removing
TGFb would increase the proliferation rate of CADASIL VSMCs to
the level of control VSMCs. Quantification analysis demonstrated a
significantly lower proliferation rate of the CADASIL PlaVSMCs
(P < .01), which addition of TGFb-neutralizing antibody restored to
control levels (Figure 3A, lower panel, P < .05). Confocal microscopy
analysis showed a significant decrease in Ki67-positive cells in
CADASIL CerVSMCs (P < .05), and the same effect of TGFb-neutra-
lizing antibody was noted in CADASIL CerVSMCs (Figure 3B, lower
panel, P < .05).
3.4 | TGFb secreted by CADASIL VSMC influences
proliferation of endothelial cells
To investigate whether TGFb produced by CADASIL VSMC affects
EC proliferation, we co-cultured ECs with CADASIL or control Pla-
and CerVSMCs using the transwell system (Figure 4). Endothelial
cells co-cultured with CADASIL Pla- and CerVSMCs exhibited a
lower proliferation rate than those co-cultured with control VSMCs
(Figure 4C and D). Neutralization of TGFb rescued the low prolifera-
tion rate of ECs co-cultured with CADASIL Pla- and CerVSMCs (Fig-
ure 4A-D, P < .05). The proliferation rate of ECs did not change in
the presence of TGFb-neutralizing antibody as shown by confocal
microscopy (Figure S4A) and neither did their morphology (Fig-
ure S4B).
To examine possible reasons for decreased EC proliferation, we
examined the expression of TGFb receptors in ECs co-cultured with
CADASIL VSMCs. Our qRT-PCR data showed that TGFbR3 was
down-regulated in ECs co-cultured with CADASIL VSMCs compared
to those cultured with control VSMCs (Figure S5). TGFb and TGFb
receptor 1 and 2 were unaltered by the presence of CADASIL
VSMCs.
4 | DISCUSSION
One of the major pathological findings of CADASIL is degeneration
of small arterioles due to the loss of myocyte cell coverage.11 Previ-
ously, we have demonstrated that VSMCs derived from patient with
CADASIL have a lower proliferation.29 In this study, we have
revealed that the lower proliferation rate of these cells affects neigh-
bouring ECs. In addition, we demonstrated that this inhibition of pro-
liferation occurs in a paracrine fashion by inhibiting cell to cell
contact using a transwell system. This paracrine mechanism seems
to be due to a compound that is secreted by VSMC, and one cyto-
kine that could potentially explain this phenomenon in CADASIL is
TGFb. By blocking this cytokine using an anti-TGFb antibody, we
were able to restore CADASIL VSMCs and ECs co-cultured with
CADASIL VSMCs to a proliferation rate that resembles the prolifera-
tion rate of ECs co-cultured with control VSMCs.
Transforming growth factor-b has been shown to be involved in
differentiation/proliferation of VSMCs.30,37 Dysregulation of the
TGFb signalling pathway has been proposed to play a role in CADA-
SIL as observed by an increased levels of the TGFb.31 The TGFb
family implication in fibrosis is most interesting as fibrotic thickening
of small vessels in CADASIL is widely reported.38 It has been sug-
gested that the damage of VSMCs in CADASIL induces secondary
fibrosis with consequent thickening of the walls and narrowing of
the lumen of cerebral arteries.19 In this study, we found elevated
expression level of TGFb isoforms (TGFb1, TGFb2 and TGFb3) in Pla-
and CerVSMCs, where the increased level of TGFb3 was more obvi-
ous as compared to the TGFb1 or TGFb2. TGFb isoforms are
expressed in the central nervous system and among them, TGFb1
has been widely considered as an injury-related cytokine which is a
F IGURE 2 Proliferation rate of foreskin fibroblasts cultured in
Cerebral autosomal-dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL) PlaVSMC-conditioned medium.
A, Human fibroblasts were incubated with PlaVSMC-conditioned
medium for 1, 3 and 7 days, stained with Ki67 antibody and
analysed by confocal microscopy. B, Umbilical artery smooth muscle
cells (UASMCs) were also incubated with CADASIL and control
PlaVSMCs-conditioned medium. C, D, qRT-PCR analysis of TGFb3
gene in Pla- and CerVSMCs. The expression of TGFb3 gene was
normalized to the endogenous control gene; HPRT1, and the RQ
(Relative Quantitation) was calculated using control VSMC
normalized to 1. **P < .01, ***P < .001. The results are
representative of three independent biological replicates (n = 3).
One-way ANOVA followed by Bonferroni’s post hoc test was used
for statistical analysis
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crucial regulator of nervous system physiology and its vasculature.
TGFb2 and TGFb3 are also localized in radial glial cells, neuronal cell
bodies in the telencephalic cortex and cerebellum, suggesting a role
in the regulation of neuronal migration and differentiation as well as
glial cell proliferation and differentiation. The expression of TGFb2
and TGFb3 persists in the entire adult CNS areas including cortex,
hippocampus, striatum, brainstem and cerebellum. In the CNS,
TGFb2 mRNA and protein are predominantly expressed in astrocytes
of white matter.39 Conclusively, the role and importance of TGFb2
in CADASIL remain unclear. Several studies have demonstrated the
ability of myofibroblasts and smooth muscle cells to express
TGFb3.40-42 TGFb3 has also been detected in uninjured epithelium.
However, distinct effects of vascular-derived TGFb3 have not been
elucidated in small vessel diseases and CADASIL. In the current
study, we found an up-regulation of TGFb3 gene expression in
CADASIL VSMCs. Other TGFb-isoforms genes were also expressed
higher in CADASIL VSMCs compared to control VSMCs. Variability
in expression of the TGFb3 gene could result in enhanced myofi-
broblast activity, proliferation and induction of ECM synthesis.43,44 A
previous study has identified elevated genes related to ECM proteins
and collagens in CADASIL.45 There is a possibility that the observed
increased secretion of TGFb-isoforms, in particular TGFb3 in our
study, could be involved in induction of ECM protein synthesis and
fibrosis formation that disrupts the normal architecture of vascula-
ture in CADASIL. Whether fibrosis is a general response to degener-
ation of VSMCs or because of the activation of TGFb-specific
fibrotic pathways is still to be examined.
Degenerative changes in capillary vessels are also involving ECs
in CADASIL and showing endothelial abnormalities which suggests a
secondary character of endothelium damage in CADASIL.46 EC func-
tion in blood vessels is regulated by coordination of vascular VEGF,
Notch and TGFb.47 Studies have shown that signalling of TGFb/
ALK1–Smad1/5 stimulates EC migration and proliferation.48 Inhibi-
tion of endoglin in ECs, which is a part of the TGFb receptor com-
plex, potentiates TGFb/ALK1 signalling,49,50 resulting in reduced
proliferation.51,52 TGFb binds to its specific receptors including
TGFbR3. TGFbR3 is one of the proteins that have a more indirect
role in TGFb signal transduction.33 The down-regulation of TGFbR3
on EC potentiates the inhibitory effect of TGFb on EC migration and
growth.50 We investigated whether TGFb receptor expression may
have an impact on EC proliferation in ECs co-cultured with CADASIL
VSMCs. Our qRT-PCR data showed down-regulation of TGFbR3 in
ECs co-cultured with CADASIL VSMCs (Table S2, Figure S5), while
TGFbR1 and TGFbR2 in ECs were unaffected (data not shown). Inter-
estingly, the presence of TGFb-neutralizing antibody significantly
changed the TGFbR3 gene expression level, which suggests that
TGFb exerts its action on EC proliferation through the TGFbR3-
receptor. This data suggest that several members of the TGFb super-
family are potentially involved in proliferation rate changes in our
system.
Several studies have demonstrated that during NOTCH target
gene activation, there is an interaction between NOTCH and TGFb
signalling pathways. Both NOTCH and TGFb are known to be
involved in many regulatory functions of VSMC and other cells, such
F IGURE 3 Treatment of Pla- and
CerVSMC with Transforming growth
factor-b (TGFb)-neutralizing antibody.
Representative confocal microscopy image
of A, Pla- and B, CerVSMCs with and
without TGFb-neutralizing antibody (upper
panels), Staining; Ki67 (green), DAPI (cell
nucleus; blue) and quantification analysis is
shown in lower panels. **P < .001,*P < .05.
The results are representative of three
independent biological replicates (n = 3).
Student t-test was used for two-group
comparisons
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as Wnt and MAP kinase signalling, cell cycle-related genes (CDC34,
CHEK1, etc.).
So far, few studies have addressed gene expression and sig-
nalling pathways in CADASIL. However, it has been shown that both
TGFb and NOTCH are involved in differentiation and proliferation of
VSMCs. In CADASIL, due to mutations in NOTCH3 gene, the synergy
between TGFb and NOTCH3 might be compromised. In this study,
increased TGFb expression was observed in CADASIL NOTCH3-
mutated VSMCs. It could therefore be expected that also other fac-
tors involved in cell proliferation, differentiation and ECM family
gene expression in VSMCs are affected. Further, changes to
NOTCH3 function due to mutations and increased TGFb in CADA-
SIL can also have an impact on TGFb receptor expression in ECs, as
shown in our study. The interplay between TGFb and NOTCH3 in
CADASIL needs further elucidation for the understanding of the
VSMCs degeneration.
We believe that increased TGFb3 reflects an inflammatory condi-
tion and even an involvement of TGFb in fibrosis in CADASIL. Sup-
port for our hypothesis is the outcome of several studies that
showed NOTCH3 and TGFb1 signalling play a key role in the patho-
genesis and progression of chronic cardiovascular disease.53 NOTCH3
was shown to be an important protective factor against cardiac fibro-
sis in a myocardial infarction model, and the protective effect of
NOTCH3 is attributable to its action on TGFb1/Smad3 signalling. This
might also occur in patients with CADASIL, where the signalling of
TGFb pathway and the effect of gene expression switch the normal
function of its action. The role of activated NOTCH signalling and
TGFb has also been shown in liver fibrosis.54 Once the intracellular
domain of the NOTCH protein (NICD) is transported into nucleus, it
can interact with a number of different transcription factors, including
FoxH1, c-Jun, c-Fos, Gli-3 and others and control expression of a
large number of target genes, including, for example, genes involved
in cell cycle control, extracellular matrix regulation and mesoderm
specification. The TGFb signalling pathway is known to be involved in
modulation of cyclin genes.55 We have also observed down-regula-
tion of cyclins gene expression in CADASIL VSMCs, suggesting that
TGFb signalling pathway may exert its effect on cyclin genes.
In CADASIL, the cells in the vasculature can be exposed to com-
plex changes, such as aggregated NOTCH3, and GOM. In this study,
we have implicated TGFb and TGFb receptors as additional players
in CADASIL disease. Therefore, more detailed studies are needed to
elucidate the interplay of TGFb signalling in the vasculature in
CADASIL. In summary, our data provide evidence for direct involve-
ment of TGFb in proliferation of VSMCs and ECs. We believe that
our findings provide a better understanding of the pathogenesis of
CADASIL disease.
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